Table 2.

Summary of response assessment in each study.

Study	Drug	Timing of response assessment	Response rate (%)
Ashraf 2013 [16]	Topotecan/cyclophosphamide	Best	63a
Bagatell 2011 [17]	Temozolomide/irinotecan	After 3 cycles	19
Di Giannatale 2014 [18]	Temozolomide/topotecan	Best	24
Garaventa 2003 [19]	Topotecan/vincristine/doxorubicin	Best	64
Kushner 2010 [20]	Cyclophosphamide/topotecan/vincristine	Best	52
Rubie 2006 [21]	Temozolomide	Best	20
Simon 2007 [22]	Topotecan/etoposide	Best	47
Simon 2007 [23]	Topotecan/cyclophosphamide/etoposide	Best	61
Mody 2017 [24]	Temozolomide/irinotecan + temsirolimus + dinutuximab	Best	6 53

^aDenotes that the response includes mixed response.